
Developing a vaccine for the zombie drug xylazine Scripps Research chemical biologists design an early proof-of-concept vaccine that could lead to the first effective treatment of xylazine overdose in people.
April 03, 2024
LA JOLLA, CA Xylazine is an FDA-approved sedative and pain reliever for use in animals, but it has severe adverse effects when used in humans. It is now illicitly being added to opioids, like fentanyl and heroin, as well as cocaine leading to a sharp rise in overdose deaths.
Now, Scripps Research chemical biologists have developed a vaccine to block the effects of xylazine's toxicity. The vaccine works by training the immune system to attack the drug, which is described in a new paper published in Chemical Communications on April 1, 2024.
We demonstrated that a vaccine can reverse the symptoms of a xylazine overdose in rodents, says study senior author Kim D. Janda, PhD, the Ely R. Callaway, Jr. Professor of Chemistry at Scripps Research. There is currently no remedy for xylazine poisoning other than supportive care, thus, we believe our research efforts and the data we have provided will pave the way for an effective treatment in humans.
The rapid increase in lethal drug overdoses attributed to xylazine combined with fentanyl prompted the White House Office of National Drug Control Policy to declare this combination an emerging threat to the United States. Xylazine intoxication presents similarly to opioid overdose, causing respiratory and central nervous system depression, and it can heighten the effects of opioids. However, naloxone typically administered to reverse the effects of opioids does not tackle the impact of xylazine, highlighting the need for effective measures to treat acute toxicity caused by xylazine.
Researchers suspect xylazine works by reducing blood flow to the brain, among other areas of the body. The drug also causes non-healing skin lesions and wounds, often located on the forearms and lower legs, that can require amputation in some cases giving it the nickname zombie drug.
Although no treatment currently exists, targeted vaccines may offer a solution. Vaccines nudge the immune system to create antibodies to fend off invaders. Antibodies can target viruses, bacteria and toxins. However, sometimes molecules are too small to initiate an immune response, as is the case with xylazine. So, to circumvent this problem, the researchers created a vaccine using a design principle that Janda pioneered, which relies on pairing the drug molecule (called a hapten) with a larger carrier molecule (a protein) and an adjuvant.
In this study, the scientists combined a xylazine hapten with multiple different protein types, to see which combination would create a robust immune response against xylazine. The team tested three vaccine formulations (termed TT, KLH and CRM197, based on the protein involved) to see which vaccine cocktail could help rodents after being challenged with xylazine. One of the three vaccines (TT) significantly increased movement in mice given xylazine after 10 minutes, while two of the three vaccines (TT and KLH) led to an improvement in breathing.
The scientists also examined how these vaccines would limit xylazine blood brain barrier, (BBB) permeation, a filtering mechanism that scrutinizes drug penetration. When xylazine was injected, it immediately crossed into the brain to bind with receptors. Antibodies typically cannot navigate the BBB; however, two of the three vaccines (TT and KLH) showed a strong ability to stop xylazine from reaching its receptors in the brain, limiting its detrimental effects.
A provisional patent has been filed on the research. In the future, his team will build off this work to create a bifunctional antibody that will reverse both fentanyl and xylazine's toxicity simultaneously, something that naloxone cannot do.
A monoclonal antibody treatment could be given in tandem with the vaccine to provide both immediate and long-term protection from both opioid substance use disorders as well as opioid-xylazine overdoses, says Janda. This strategy could make a significant impact on the opioid epidemic.
Evaluation of a Hapten Conjugate Vaccine Against the Zombie Drug' Xylazine was co-authored by Mingliang Lin, Lisa M. Eubanks, Bin Zhou, and Kim D. Janda, all of Scripps Research.
Funding for the study was provided by the Shadek family and Pearson Foundation.
Chemistry Janda, Kim
Most recent headlines
05/01/2027
Worlds first 802.15.4ab-UWB chip verified by Calterah and Rohde & Schwarz to be ...
07/10/2026
Dalet, a leading technology and service provider for media-rich organizations, today announced the latest Long-Term Supported (LTS) release of Dalet Flex. Build...
06/09/2026
June 9 2026, 23:00 (PDT) Dolby and MagentaTV Bring Fans Closer to the FIFA Worl...
04/08/2026
Live production in the cloud is a growing trend across the industry, and Major L...
04/08/2026
LAFC co-managing owner will succeed Don Garber on Jan. 1, 2027, as league prepar...
04/08/2026
In 2022, when the PGA TOUR was breaking ground on its new, state-of-the-art broa...
04/08/2026
Provided by POVORA, the new camera angle offers a dealer's-eye view of the c...
04/08/2026
Spiideo will provide the camera setup, with NEP handling broadcast integration and off-site video operations...
04/08/2026
Production team streamed more than 750 youth rugby matches using ATEM switchers,...
04/08/2026
Agreement gives KTC early access to NDI's Advanced SDK for integration across commercial displays, digital signage, and interactive panels...
04/08/2026
Twelve projects across four categories recognize collaborative work in productio...
04/08/2026
Multi-year agreement will introduce SkeleTRACK, semi-automated offside, automate...
04/08/2026
Three mc 56 consoles, dual A__UHD Core engines, RAVENNA networking, and HOME management supported live sound, monitoring, and international broadcast production...
04/08/2026
New contribution products support ultra-low-latency video transport across fixed, remote, and mobile production environments...
04/08/2026
Company will showcase updates across PRIME, Chyron LIVE, Paint, virtual production, newsroom workflows, and venue control...
04/08/2026
Exhibit will feature SilverBack, VersaBrix, VersaFrame, VF-9100, and FiberSaver-10G platforms...
04/08/2026
Platform updates target cloud-based production, high-density ST 2110 monitoring,...
04/08/2026
LMG will take control of Gravity Media's U.S. mobile-unit fleet as the compa...
04/08/2026
Amp-modelling rigs get major upgrade
HeadRush have recently released a major firmware update that brings some powerful new features to their Prime, Core and...
04/08/2026
Generate a choir from a single voice track
Following years of development, Am I Audio have just officially launched their debut plug-in. Created in collabor...
04/08/2026
Official EMT-endorsed reverbs now available to all
Two more of Universal Audio's renowned UAD plug-ins have just gained new native versions that can be ...
04/08/2026
SBS helps Australians understand why every Census counts
Media releases
As Australia prepares for the 2026 Census on Tuesday 11 August, SBS is helping ensur...
04/08/2026
Canada invests in the future of HF communications with Rohde & Schwarz solutions After selection by the Canadian Department of National Defence (DND) as the p...
04/08/2026
Blendkit Expands Beyond Blender
Brie Clayton August 4, 2026
0 Comments
Popular 3D Asset Library Launches Alpha Plugins for Maya, Godot, and Rhino
Blend...
04/08/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
04/08/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
04/08/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
04/08/2026
Ikegami has chosen the 11-14 September 2026 International Broadcasting Convention in Amsterdam as the European market launch venue for additions to its UNICAM p...
04/08/2026
Appear (IBC2026 booth 1.C61) will showcase new X & VX Platform capabilities that extend broadcast-grade performance from venue to cloud
Appear ASA (OSE: APR), ...
04/08/2026
LiveU, the global leader in live IP-video solutions, today highlighted the crucial role its EcoSystem played in Broadcast Management Group's (BMG) successfu...
04/08/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
04/08/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
04/08/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
04/08/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
04/08/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
04/08/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
04/08/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
04/08/2026
Homecoming Artist Spotlight: Dreion The singer, songwriter, and producer talks about finding his village at Berklee ahead of his Homecoming performance on Sep...
04/08/2026
Tuesday 4 August 2026
Sky Sports agrees deal with SANZAAR for international rugby rights 2026 - 2030
The deal means Sky will have exclusive rights to the inau...
04/08/2026
Kill Tony Launches on Supercast, Giving Fans Premium & Ad-Free Access to Comedy&...
04/08/2026
More details coming soon....
04/08/2026
More details coming soon....
04/08/2026
More details coming soon....
04/08/2026
Surging AI demands are driving the need for massive datasets and context windows that burst past the confines of system memory.
But rising needs aren't me...
04/08/2026
For robotaxis and other autonomous vehicles (AVs), the hardest problems aren'...
04/08/2026
Members of the Open Secure AI Alliance - now more than 120 organizations strong - are developing new guidelines to strengthen agentic AI cybersecurity as the an...
04/08/2026
Dalet, a leading technology and service provider for media-rich organizations, t...
03/08/2026
SVG's annual TranSPORT conference returns to New York City for a full day of sessions focused on the current state of live-sports-transmission technology. S...
03/08/2026
A five-time Emmy winner, this esports vet has built a production career on live storytelling, audience connection, and meeting viewers wherever they are
The sp...
03/08/2026
Live production in the cloud is a growing trend across the industry and Major Le...